BVS

Bioventus Inc. (BVS) | Rumor.io

Bioventus

BVS

Attention (50-day avg)0.01%

Attention rank (50-day avg)#568

Bullish sentiment (50-day avg)100%

Price to earnings ratio17.7

Market capitalization957.6M

Earnings per share0.78

Dividend yield (TTM)—

Revenue (annual)568.1M

Net income (annual)27.3M

Social

What share of all stock conversation is about BVS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% -0.01	0% +0

Jul 6

Bioventus Inc. (BVS) shares rose after Medicare reversed reimbursement cuts for the company's non-invasive bone growth stimulators.
BVS stock is experiencing strong growth, up 12% and sitting under the 52-week high around $12, with daily RSI stretched into the mid 70s.
BVS has a niche market position as a microcap stock with weak earnings growth and cash flow pressure, making it difficult to break out of the upward trend.

Generated by AI

Sentiment

Of the messages about BVS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	61.65% -30.84
Bearish	—	—	0% 0	38.35% +30.84

Bullish· May 19

Bioventus Inc. ($BVS) experienced a 12.5% price increase, contributing to a 15.6% daily gain.
The stock has a medium float, high relative volume, and a short float of 0.0%, indicating potential for further price appreciation.
Bioventus Inc. ($BVS) has gained over 26% since the author's last tweet, with a strong possibility of continued price rise.

Bearish· Feb 28

$BVS may be due for a pullback, as it failed to close above a key resistance level and its recent price movement has been too aggressive.
Bioventus Inc. may be struggling to pay off its significant debt, which could lead to bankruptcy and a sharp decline in its stock price.
The company's chart appears unhealthy, with a bearish flag pattern and oversold RSI indicator, suggesting that the stock may continue to decline in the near future.

Generated by AI

Topics

Of the messages about BVS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	33.48%
Announcements	—	—	—	0.16%
Analysts	—	—	—	33.19%
Earnings	—	—	—	0.02%
Macro	—	—	—	33.15%
Controversies	—	—	—	0%

May 19

Bioventus Inc. (BVS) has agreed to sell its Wound business to LifeNet Health for $85 million in cash and potential earn-out payments.
Bioventus Inc. (BVS) stock price has increased by over 26% since the last update.
Bioventus Inc. (BVS) has released its 2023 Q1 results, including an earnings call presentation, providing insights into the company's performance.

Generated by AI

Community

Of the messages about BVS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	2.97%
Newcomers	100%	100%	100%	97.03%

Regulars· May 7

Bioventus reported a GAAP EPS of -$0.07, beating estimates, and revenue of $129.45M, also exceeding expectations.
The company has raised its 2024 guidance, expecting net sales of $535M-$550M and adjusted EPS of $0.25 to $0.33, compared to previous estimates.
Bioventus shares have been volatile, with a 10.42% increase in the last 20 minutes, a 14.04% decline in the same period, and a 13.30% drop in the last 3 minutes.

Newcomers· May 7

Bioventus Inc. (BVS) raised its FY '24 financial guidance, reflecting enhanced revenue growth and strong execution of strategic priorities, causing shares to climb 30%.
The stock's Q1 results showed an 8.7% revenue increase, and the full-year 2024 guidance was enhanced, contributing to a +28% jump in the stock's value.
Bioventus' first quarter financial results included a strong Q1 performance, with the stock showing a premarket change of 18.50% and a significant increase in volume.

Generated by AI

News

Bioventus: Cash Flow Anchors The Bull Case Beyond A Potential Sale (NASDAQ:BVS)

Bioventus benefits from improved financing flexibility, with a term loan maturity extended to 2030 and a 75 bps interest margin reduction. See why BVS is a Buy.

9d agoSeeking Alpha

Are Medical Stocks Lagging Bioventus (BVS) This Year?

Here is how Bioventus (BVS) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

1mo agoYahoo Finance

Bioventus (BVS) Q2 2026 Earnings Call Transcript

Motley Fool Press Release.

1mo agotheglobeandmail.com

Bioventus (BVS) Stock Still Looks Like A Bargain On Earnings

Bioventus stock has delivered strong share price gains over the past few years, yet current valuation checks still suggest it screens as relatively cheap on several metrics. That combination of a big historical return with an apparently supportive valuation is what current and prospective shareholders are trying to interpret. Over the last 3 years Bioventus has returned about 198%, which puts a spotlight on whether the current price already reflects much of the good news that investors...

1mo agoYahoo Finance

The Bull Case For Bioventus (BVS) Could Change Following Its Q2 Earnings Surge And Reaffirmed 2026 Guidance

In early August 2026, Bioventus Inc. reported second-quarter sales of US$153.21 million and net income of US$33.44 million, sharply higher than a year earlier, and reaffirmed its full-year 2026 net sales guidance of US$600 million to US$610 million. The combination of rising sales, a substantial jump in earnings per share, and management’s confidence in its 2026 outlook highlights improved operational performance and profitability momentum across Bioventus’ portfolio. Now we’ll examine how...

1mo agoYahoo! Finance Canada

Bioventus Inc. Q2 2026 Earnings Call Summary

1mo agoYahoo Finance

Also Discussed

Investors talking about BVS also mention

#	Name	Attention
1	Invesco Dorsey Wright Industrials Momentum ETFPRN	0%0
2	The Eastern CompanyEML	0%new
3	SunCar Technology Group Inc. Class A Ordinary SharesSDA	0%0
4	Life360, Inc.LIF	0%0
5	PIMCO New York Municipal Income Fund IIPNI	0.01%-0.01
6	Prestige Consumer Healthcare Inc.PBH	0%0
7	WisdomTree Emerging Markets Local Debt FundELD	0%new
8	DVP - Roundhill Acquirers Deep Value ETF	——
9	Nuveen New York Quality Municipal Income FundNAN	0%new
10	National HealthCare CorporationNHC	0%0

Bioventus Inc.

Healthcare
Medical Devices

Bioventus Inc. Class A Common Stock represents Bioventus Inc., a medical technology company focused on developing and commercializing products for musculoskeletal care and active healing. Bioventus serves patients and healthcare providers with orthobiologic and restorative solutions designed to support bone healing, pain treatment, and recovery from a range of orthopedic conditions. Its current business is organized around active healing therapies, surgical solutions, and related products used in both U.S. and international markets. The company’s portfolio includes therapies such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture-healing technologies. Bioventus operates as a specialized healthcare company within the broader medical device sector, with offerings aimed at non-surgical and surgical treatment settings.

Website

Location

4721 Emperor Boulevard

Durham, NC, 27703

United States

Social

What share of all stock conversation is about BVS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% -0.01	0% +0

Jul 6

Bioventus Inc. (BVS) shares rose after Medicare reversed reimbursement cuts for the company's non-invasive bone growth stimulators.
BVS stock is experiencing strong growth, up 12% and sitting under the 52-week high around $12, with daily RSI stretched into the mid 70s.
BVS has a niche market position as a microcap stock with weak earnings growth and cash flow pressure, making it difficult to break out of the upward trend.

Generated by AI

Sentiment

Of the messages about BVS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	61.65% -30.84
Bearish	—	—	0% 0	38.35% +30.84

Bullish· May 19

Bioventus Inc. ($BVS) experienced a 12.5% price increase, contributing to a 15.6% daily gain.
The stock has a medium float, high relative volume, and a short float of 0.0%, indicating potential for further price appreciation.
Bioventus Inc. ($BVS) has gained over 26% since the author's last tweet, with a strong possibility of continued price rise.

Bearish· Feb 28

$BVS may be due for a pullback, as it failed to close above a key resistance level and its recent price movement has been too aggressive.
Bioventus Inc. may be struggling to pay off its significant debt, which could lead to bankruptcy and a sharp decline in its stock price.
The company's chart appears unhealthy, with a bearish flag pattern and oversold RSI indicator, suggesting that the stock may continue to decline in the near future.

Generated by AI

Topics

Of the messages about BVS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	33.48%
Announcements	—	—	—	0.16%
Analysts	—	—	—	33.19%
Earnings	—	—	—	0.02%
Macro	—	—	—	33.15%
Controversies	—	—	—	0%

May 19

Bioventus Inc. (BVS) has agreed to sell its Wound business to LifeNet Health for $85 million in cash and potential earn-out payments.
Bioventus Inc. (BVS) stock price has increased by over 26% since the last update.
Bioventus Inc. (BVS) has released its 2023 Q1 results, including an earnings call presentation, providing insights into the company's performance.

Generated by AI

Community

Of the messages about BVS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	2.97%
Newcomers	100%	100%	100%	97.03%

Regulars· May 7

Bioventus reported a GAAP EPS of -$0.07, beating estimates, and revenue of $129.45M, also exceeding expectations.
The company has raised its 2024 guidance, expecting net sales of $535M-$550M and adjusted EPS of $0.25 to $0.33, compared to previous estimates.
Bioventus shares have been volatile, with a 10.42% increase in the last 20 minutes, a 14.04% decline in the same period, and a 13.30% drop in the last 3 minutes.

Newcomers· May 7

Bioventus Inc. (BVS) raised its FY '24 financial guidance, reflecting enhanced revenue growth and strong execution of strategic priorities, causing shares to climb 30%.
The stock's Q1 results showed an 8.7% revenue increase, and the full-year 2024 guidance was enhanced, contributing to a +28% jump in the stock's value.
Bioventus' first quarter financial results included a strong Q1 performance, with the stock showing a premarket change of 18.50% and a significant increase in volume.

Generated by AI

Bioventus

Social

Jul 6

Bullish· May 19

Bearish· Feb 28

May 19

Regulars· May 7

Newcomers· May 7

Bioventus: Cash Flow Anchors The Bull Case Beyond A Potential Sale (NASDAQ:BVS)

Are Medical Stocks Lagging Bioventus (BVS) This Year?

Bioventus (BVS) Q2 2026 Earnings Call Transcript

Bioventus (BVS) Stock Still Looks Like A Bargain On Earnings

The Bull Case For Bioventus (BVS) Could Change Following Its Q2 Earnings Surge And Reaffirmed 2026 Guidance

Bioventus Inc. Q2 2026 Earnings Call Summary

Also Discussed

Bioventus Inc.

Company Information

Location

Bioventus: Cash Flow Anchors The Bull Case Beyond A Potential Sale (NASDAQ:BVS)

Are Medical Stocks Lagging Bioventus (BVS) This Year?

Bioventus (BVS) Q2 2026 Earnings Call Transcript

Bioventus (BVS) Stock Still Looks Like A Bargain On Earnings

The Bull Case For Bioventus (BVS) Could Change Following Its Q2 Earnings Surge And Reaffirmed 2026 Guidance

Bioventus Inc. Q2 2026 Earnings Call Summary

Also Discussed

Social

Jul 6

Bullish· May 19

Bearish· Feb 28

May 19

Regulars· May 7

Newcomers· May 7